Literature DB >> 21539695

Survey of current prophylaxis practices and bleeding characteristics of children with severe haemophilia A in US haemophilia treatment centres.

M V Ragni1, P J Fogarty, N C Josephson, A T Neff, L J Raffini, C M Kessler.   

Abstract

Every other day (qod) factor VIII prophylaxis prevents joint bleeds in children with severe haemophilia A. Although three times weekly or qod prophylaxis is recommended by the National Hemophilia Foundation (NHF), how widely these practices have been adopted is not known. We sought to define current prophylaxis practices at US haemophilia treatment centres (HTCs). An email survey was distributed to US HTCs, utilizing web-based membership rosters of the Centers for Disease Control (CDC) and the Hemostasis Thrombosis Research Society (HTRS). Of 62 HTCs responding, prophylaxis is initiated on a three times weekly schedule in 29 (46.8%), twice weekly in 13 HTCs (21.0%) and once weekly in 20 HTCs (32.2%). Central venous catheters are used to infuse factor prophylactically at 55 HTCs (88.7%), including in 100% of children initiating prophylaxis at 19 HTCs (30.6%) and in 50% of those at 41 HTCs (66.1%), but avoided altogether at seven HTCs (11.3%). Prophylaxis is initiated after one or more bleeds in 56 HTCs (90.3%), but after the first bleed in only 28 HTCs (25.2%). Among 226 newborns with severe haemophilia A in 62 HTCs, 1.82 births/HTC/year, the median age at first bleed, excluding circumcision, is 7 months. Of the 113 (53.5%) newborns who underwent circumcision, 62 (54.9%) bled. Despite a recommended standard of three times weekly prophylaxis, over half of surveyed HTCs do not follow these guidelines, and nearly one-third begin prophylaxis on a once weekly schedule to delay or avoid the need for central venous access.
© 2011 Blackwell Publishing Ltd.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21539695     DOI: 10.1111/j.1365-2516.2011.02554.x

Source DB:  PubMed          Journal:  Haemophilia        ISSN: 1351-8216            Impact factor:   4.287


  10 in total

1.  Rationale for a randomized controlled trial comparing two prophylaxis regimens in adults with severe hemophilia A: the Hemophilia Adult Prophylaxis Trial.

Authors:  Margaret V Ragni
Journal:  Expert Rev Hematol       Date:  2011-10       Impact factor: 2.929

Review 2.  New and Emerging Agents for the Treatment of Hemophilia: Focus on Extended Half-Life Recombinant Clotting Proteins.

Authors:  Margaret V Ragni
Journal:  Drugs       Date:  2015-09       Impact factor: 9.546

3.  The importance of genetic factors for the development of arthropathy: a longitudinal study of children and adolescents with haemophilia A.

Authors:  Edward D Gomperts; John Schwarz; Sharyne M Donfield; Alice E Lail; Jan Astermark; W Keith Hoots; Cheryl A Winkler; Erik Berntorp
Journal:  Thromb Haemost       Date:  2016-12-08       Impact factor: 5.249

4.  A bispecific antibody to factors IXa and X restores factor VIII hemostatic activity in a hemophilia A model.

Authors:  Takehisa Kitazawa; Tomoyuki Igawa; Zenjiro Sampei; Atsushi Muto; Tetsuo Kojima; Tetsuhiro Soeda; Kazutaka Yoshihashi; Yukiko Okuyama-Nishida; Hiroyuki Saito; Hiroyuki Tsunoda; Tsukasa Suzuki; Hideki Adachi; Taro Miyazaki; Shinya Ishii; Mika Kamata-Sakurai; Takeo Iida; Aya Harada; Keiko Esaki; Miho Funaki; Chifumi Moriyama; Eriko Tanaka; Yasufumi Kikuchi; Tetsuya Wakabayashi; Manabu Wada; Masaaki Goto; Takeshi Toyoda; Atsunori Ueyama; Sachiyo Suzuki; Kenta Haraya; Tatsuhiko Tachibana; Yoshiki Kawabe; Midori Shima; Akira Yoshioka; Kunihiro Hattori
Journal:  Nat Med       Date:  2012-09-30       Impact factor: 53.440

5.  Anti-factor IXa/X bispecific antibody ACE910 prevents joint bleeds in a long-term primate model of acquired hemophilia A.

Authors:  Atsushi Muto; Kazutaka Yoshihashi; Minako Takeda; Takehisa Kitazawa; Tetsuhiro Soeda; Tomoyuki Igawa; Zenjiro Sampei; Taichi Kuramochi; Akihisa Sakamoto; Kenta Haraya; Kenji Adachi; Yoshiki Kawabe; Keiji Nogami; Midori Shima; Kunihiro Hattori
Journal:  Blood       Date:  2014-10-01       Impact factor: 22.113

6.  Prophylaxis therapy in paediatric patients with haemophilia: a survey of clinical management trends in Italy.

Authors:  Giancarlo Castaman; Angiola Rocino; M Gabriella Mazzucconi; Ezio Zanon; Fabio Gagliano; Angelo C Molinari
Journal:  Blood Transfus       Date:  2015-05-14       Impact factor: 3.443

7.  Design of the INHIBIT trial: preventing inhibitors by avoiding 'danger', prolonging half-life and promoting tolerance.

Authors:  Margaret V Ragni; Lynn M Malec
Journal:  Expert Rev Hematol       Date:  2014-11-05       Impact factor: 2.929

8.  Both hemophilia health care providers and hemophilia a carriers report that carriers have excessive bleeding.

Authors:  Allison Paroskie; Olatunde Oso; Benjamin Almassi; Michael R DeBaun; Robert F Sidonio
Journal:  J Pediatr Hematol Oncol       Date:  2014-05       Impact factor: 1.289

9.  Identification and multidimensional optimization of an asymmetric bispecific IgG antibody mimicking the function of factor VIII cofactor activity.

Authors:  Zenjiro Sampei; Tomoyuki Igawa; Tetsuhiro Soeda; Yukiko Okuyama-Nishida; Chifumi Moriyama; Tetsuya Wakabayashi; Eriko Tanaka; Atsushi Muto; Tetsuo Kojima; Takehisa Kitazawa; Kazutaka Yoshihashi; Aya Harada; Miho Funaki; Kenta Haraya; Tatsuhiko Tachibana; Sachiyo Suzuki; Keiko Esaki; Yoshiaki Nabuchi; Kunihiro Hattori
Journal:  PLoS One       Date:  2013-02-28       Impact factor: 3.240

10.  Patient and parent preferences for characteristics of prophylactic treatment in hemophilia.

Authors:  Roberto Furlan; Sangeeta Krishnan; Jeffrey Vietri
Journal:  Patient Prefer Adherence       Date:  2015-11-23       Impact factor: 2.711

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.